Why wasn't EBITDA guidance raised more given the impressive Q2 margins, and was there any tariff refund benefit this quarter?

Management confirmed no tariff benefit in Q2. They raised full-year adjusted EBITDA guidance and are excited about the leverage, but also plan to make strategic investments in H2 for future growth in areas like primary care, innovative channels, and sleep, balancing profitability with growth. “No, there was not a tariff benefit realized in the quarter. So that was not part of the 19% adjusted EBITDA margin that we delivered in the quarter.”

Does Vital Connect primarily target new opportunities like inpatient monitoring and hospital-at-home, and is it the deal for expanding into other modalities like sleep apnea?

Management confirmed that Vital Connect accelerates iRhythm's roadmap for hospital monitoring, hospital-to-home programs, and remote patient monitoring (RPM) due to its multivital capabilities. These are seen as synergistic with iRhythm's overall strategy and represent incremental market opportunities valued in the billions, going beyond just the MCT market. “But MCT alone is not the only reason that we're interested and excited about Vital Connect. So you hit the nail on the head with respect to those incremental ancillary market opportunities that I do think can be valued in the billions of dollars in terms of market potential.”

What are the early learnings from direct-to-patient marketing initiatives, and will the program expand?

Management expects to continue expanding direct-to-patient initiatives, which are part of the incremental H2 spend. While it's too early to measure results from the initial efforts, confidence is high, and they are excited about the potential returns. “You certainly, Marie, should expect that we're going to continue to lean into and expand it. And that's part of the incremental spend in the back part of the year that Dan was alluding to.”

IRTC

iRhythm Holdings (IRTC) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 6, 2026

Source: earnings call transcript

Executive summary

iRhythm Holdings, Inc. Q2 FY26 — Strong Growth, Margin Expansion, and Strategic Acquisition

iRhythm delivered a robust second quarter, driven by sustained demand for Zio products and strong commercial execution across all channels. The strategic acquisition of Vital Connect is set to expand the company's cardiac monitoring capabilities, particularly in the MCT market and into new areas like multivital and inpatient monitoring. Management remains focused on balancing profitable growth with strategic investments in innovation and market expansion, while addressing regulatory and operational challenges.

Highlights

Revenue reached $224.2 million, up 20.1% year-over-year, marking the seventh consecutive quarter of over 20% growth.
Adjusted EBITDA was $43.3 million, or 19.3% of revenue, an improvement of over 1,000 basis points year-over-year.
Gross margin expanded to 72.8%, an increase of 160 basis points year-over-year.
Free cash flow was a record positive $37.5 million.
FDA clearance of third-generation algorithm expected to reduce technician review time by 50% and generate $100 million in cumulative cost savings over 5 years.

Concerns

Litigation settlement payment of $50 million to Baxter and its subsidiaries.
Ongoing FDA warning letter review process, with timing of resolution remaining with the agency.
Cybersecurity incident in June resulted in data exfiltration, though no material impact to operations or financials.

Guidance & targets

Category	Target	Timeline	Confidence
Full-year 2026 Revenue	$880 million to $890 million high materiality	FY 2026	High
Full-year 2026 Adjusted EBITDA Margin	13% to 14% high materiality	FY 2026	High
Q3 2026 Revenue	$221 million to $223 million medium materiality	Q3 · 2026	High
Q3 2026 Adjusted EBITDA Margin	12% to 13% medium materiality	Q3 · 2026	High
Adjusted EBITDA Margin Target	15% high materiality	FY 2027	High
Zio MCT Clearance	First half of 2027 medium materiality	H1 2027	Medium
Vital Connect Revenue Contribution	Positive contribution to revenue growth high materiality	Beginning 2027 and thereafter	High
Third-generation Algorithm Launch	First half of 2027 medium materiality	H1 2027	High
Cumulative Cost Savings from Third-generation Algorithm	$100 million medium materiality	Over 5 years	High
Free Cash Flow	Increase year-over-year medium materiality	FY 2026	High

Product announcements

Product	Type	Timeline	Details
Third-generation Algorithm	milestone	First half of 2027 launch

Deals & partnerships

Vital Connect Acquisition of a complementary cardiac monitoring platform supporting 4 modalities (MCT, event monitoring, long-term continuous monitoring, short-term Holter) and FDA-cleared for continuous patient monitoring in hospitals.

The acquisition expands iRhythm's capabilities beyond ambulatory cardiac monitoring, across the continuum of care, and into the MCT segment with a broader feature set. It also provides a foundation for multivital monitoring and additional care settings.

Luum Partnership to combine predictive identification workflows with iRhythm monitoring solutions.

Signed 2 commercial agreements intended to support earlier diagnosis and intervention for patients at risk for arrhythmias.

Desert Oasis Healthcare Expanding predictive arrhythmia solutions work.

Using AI-driven analytics to identify patients who may benefit from cardiac evaluation and monitoring.

Risks & headwinds

FDA Warning Letter

Ongoing

Mitigation:Updated the agency on completion of remediation activities and self-initiated third-party audit; focused on supporting the process and responding to requests.

Litigation Settlement

$50 million payment

Mitigation:Settled outstanding litigation with Baxter and its subsidiaries, Welch Allyn and Bardy Diagnostics, allowing for greater clarity and focus on strategic initiatives.

Cybersecurity Incident June 2026

Certain data exfiltrated

Mitigation:Promptly activated response plan, engaged external experts, notified law enforcement. Incident contained, root cause identified, no material impacts to products, patient care, business operations or financial results.

What to watch in Q3 FY26

Vital Connect Integration & Commercial Launch

Early 2027

Current Acquisition announced, expected to close by year-end 2026.

Target Successful integration into iRhythm's commercial team and nationwide launch.

Why it matters

This integration is key to realizing the strategic benefits of the acquisition, expanding MCT market access, and leveraging new capabilities like multivital monitoring.

We expect that to close by the end of the year, and our focus is going to be integrating this into the commercial team in the very first part of next year.

Find out whether IRTC delivers this. Inve re-checks your case every morning.

Q&A highlights

How will Vital Connect's MCT offering be positioned against Zio AT and the upcoming Zio MCT, and how will it accelerate iRhythm's MCT category?

Management stated that a multi-product offering is necessary for the diverse MCT market. Vital Connect's patch expands market access to the remaining 50% of the MCT market (an incremental $500M opportunity) that Zio AT couldn't serve, due to features like 30-day monitoring, live-looking, and 4-in-1 capability. The focus will be on integrating Vital Connect into the commercial team early next year.

“Vital Patch opens up the remaining 50% of that market. Even our own Zio MCT product would only open up probably another 20% to 30%. So having Vital Patch in there gives us access to the entire market, which is probably a $1 billion market, growing in the high single digits. It's probably an incremental $500 million market opportunity for us.”

asked by John Young · answered by Quentin Blackford

3 min read 6 chapters

Detailed narrative

Vital Connect Acquisition

iRhythm announced the acquisition of Vital Connect, a move expected to significantly expand its cardiac monitoring capabilities. Vital Connect brings a complementary platform supporting four cardiac monitoring modalities, including mobile cardiac telemetry (MCT), event monitoring, long-term continuous monitoring, and short-term Holter.

The technology is also FDA-cleared for continuous patient monitoring in hospitals, expanding iRhythm's reach beyond ambulatory care. This acquisition is anticipated to strengthen iRhythm's long-term growth profile, with Vital Connect currently at an approximately $65 million annual revenue run rate, and contribute positively to revenue growth starting in 2027.

MCT Strategy and Product Roadmap

The acquisition of Vital Connect is central to iRhythm's multi-product strategy for the MCT market, which is estimated to be a $1 billion market. Vital Connect's platform addresses the remaining 50% of the MCT market that Zio AT could not serve, offering features like 30-day monitoring, live-looking capabilities, and 4-in-1 device functionality.

While the company remains committed to Zio MCT and aims for its clearance in H1 2027, the immediate focus post-acquisition will be on integrating Vital Connect's products into iRhythm's commercial force to capitalize on its broader market access and advanced features.

Upstream Strategy and Primary Care Expansion

iRhythm is actively pursuing an upstream strategy to reach patients earlier in their care journey, particularly the 27 million people at risk for arrhythmias in the U.S. who often first engage with primary care. This includes commercial agreements with Luum for predictive identification workflows and a partnership with Desert Oasis Healthcare using AI-driven analytics.

The company launched direct-to-patient initiatives through the patient point network to increase awareness and streamline connections between primary care and cardiology, with early pilot programs showing over 85% accuracy in identifying clinically relevant arrhythmias.

Technology Integration and International Growth

Technology integration is a key enabler of iRhythm's growth, with approximately 60% of volume from EHR-integrated accounts and nearly 80 of the top 100 customers integrated. This reduces friction and improves efficiency in provider workflows. Internationally, iRhythm is building momentum in the U.K. with the NHS, deepening relationships in the Netherlands, and benefiting from a higher reimbursement rate in Japan effective June 1.

These efforts are supported by clinical evidence generation and disciplined commercialization.

Regulatory and Litigation Updates

iRhythm achieved FDA clearance for its third-generation algorithm, which is expected to launch in H1 2027 and significantly improve efficiency and reduce costs. The company continues to work with the FDA on its warning letter, having updated the agency on remediation activities and a third-party audit.

Additionally, iRhythm settled outstanding litigation with Baxter and its subsidiaries for a payment of $50 million, resolving the matter and allowing for greater focus on strategic initiatives.

Cybersecurity Incident and Sleep Apnea Opportunity

A cybersecurity incident identified on June 8 was contained, with the root cause identified and no material impact to products, patient care, business operations, or financial results. The company also continues to explore the sleep apnea market, which represents a large and underpenetrated opportunity with approximately 40 million U.S. patients.

Pilot programs are underway to refine strategy and streamline fragmented workflows, with encouraging potential for future growth.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.